health
FDA grants accelerated approval to camizestrant for ESR1-mutated advanced breast cancer
The FDA has approved camizestrant with a CDK4/6 inhibitor for selected patients whose HR-positive, HER2-negative advanced breast cancer develops an ESR1 mutation during first-line therapy.